TWiV 1064: Clinical update with Dr. Daniel Griffin
Episode description
In his weekly clinical update, Dr. Griffin discusses progress toward measles elimination, risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune-suppressive drugs, symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals, late administration and corticosteroid usage explain inefficacy in COVID-19 convalescent plasma trial, higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19, recombinant C1 inhibitor in the prevention of severe COVID-19, and Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Progress toward measles elimination (CDC)
- Risk of severe COVID-19 despite vaccination in patients using immune-suppressive drugs (TID)
- Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to untreated individuals (CID)
- Late administration and corticosteroid usage explain inefficacy in COVID-19 convalescent plasma trial (JID)
- Higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19 (JAMA)
- Recombinant C1 inhibitor in the prevention of severe COVID-19 (FII)
- Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with SARS-CoV-2 disease course (BMC)
- Contribute to our MicrobeTV fundraiser at PWB 37:55
- Letters read on TWiV on TWiV 1062 38:16
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]